Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the six-month period from May 1, 2015, to October 31, 2015. The document serves as a Block Listing Six Monthly Return, detailing the status of various employee share option and savings-related share schemes. It does not contain general business operations updates or financial performance data.
Key Financial Metrics
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly limited to equity scheme administration data.
Material Changes in Equity Schemes
The filing reports changes in the balance of unallotted securities across multiple schemes. Notable movements include:
- GlaxoSmithKline Share Option Plan - Ordinary Shares: Increased by 5,000,000 shares; 319,341 shares were issued. Ending balance: 8,399,729.
- GlaxoSmithKline Share Option Plan - ADS: Increased by 13,000,000 shares; 246,436 shares were issued. Ending balance: 10,386,068.
- GlaxoSmithKline plc Sharesave plan 2012: Increased by 3,539,000 shares; 94,758 shares were issued. Ending balance: 3,603,722.
- Other Schemes: The Glaxo Wellcome UK, Glaxo Wellcome International, Glaxo Wellcome 1999, SmithKline Beecham 1989 (Approved/Unapproved), and GlaxoSmithKline Savings Related Share Option Scheme reported no increases or issuances during the period, maintaining their previous balances.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is a regulatory compliance report regarding share scheme inventory.
Investor Verification Checklist
- Verify the total number of shares available for future issuance under the primary GSK Share Option Plans (Ordinary and ADS) following the reported increases.
- Confirm the dilution impact of the 660,535 total shares issued across all schemes during the six-month period.
- Review the specific terms of the "Sharesave plan 2012" to understand the conditions attached to the 3,539,000 share increase.
- Note that this filing contains no financial performance data; refer to the company's Form 20-F or interim financial reports for revenue and profit metrics.